Ac Immune Sa stock is traded at $2.26, with a volume of 91,489. It is down -1.31% in the last 24 hours and down -7.76% over the past month. AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Previous Close:
$2.29
Open:
$2.32
24h Volume:
91,489
Relative Volume:
0.39
Market Cap:
$224.70M
Revenue:
$4.60M
Net Income/Loss:
-$82.31M
P/E Ratio:
-
EPS:
-$0.8202
Net Cash Flow:
-$87.79M
1W Performance:
+7.11%
1M Performance:
-7.76%
6M Performance:
-18.41%
1Y Performance:
-31.10%
1-Day Range:
$2.23$2.33
1-Week Range:
$2.10$2.55
52-Week Range:
$2.02$3.90
Ac Immune Sa Stock (ACIU) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS